ABCL AbCellera Biologics Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.97

Period return

+1.33 (+28.66%)

Volume

5.1M

2026-07-21O $5.79 H $6.05 L $5.54 C $5.97MA5 $6.23MA20 $6.93MA60 $5.68MA120 $4.58

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.03%
2026. 05. 06.MediumBUY3 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 04. 10.MediumBUY3 months ago
Jones Trading: Buy
US analyst rating / recommendation change.
2025. 11. 07.MediumHOLD9 months ago
Leerink Partners: Market Perform
US analyst rating / recommendation change.
2025. 08. 08.LowBUY12 months ago
Stifel: Buy
US analyst rating / recommendation change.
2025. 07. 14.LowBUYlast year
Keybanc: Overweight
US analyst rating / recommendation change.
2025. 05. 17.LowBUYlast year
Truist Securities: Buy
US analyst rating / recommendation change.
2025. 05. 10.LowBUYlast year
Stifel: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $10.43 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Sector: Healthcare
Industry: Biotechnology
HQ: Vancouver, BC, Canada
Fiscal year end: —
Employees: 562
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.17	—	—	$7.85M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.15	—	—	$4.24M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.44	—	—	$23.78M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.26	—	—	$17.28M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	10,562,065	$36.86M	0.03%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	5,810,985	$19.87M	0.03%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,149,325	$4.01M	0.01%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	976,507	$3.34M	0.01%	—	New position

AbCellera Biologics Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 06.	Cantor Fitzgerald	—	Initiate coverage	— → Overweight	—	Cantor Fitzgerald: Overweight
2026. 04. 10.	Jones Trading	—	Initiate coverage	— → Buy	—	Jones Trading: Buy
2025. 11. 07.	Leerink Partners	—	Downgrade	Outperform → Market Perform	—	Leerink Partners: Outperform → Market Perform
2025. 08. 08.	Stifel	—	Maintain	Buy → Buy	—	Stifel: Buy
2025. 07. 14.	Keybanc	—	Maintain	Overweight → Overweight	—	Keybanc: Overweight
2025. 05. 17.	Truist Securities	—	Maintain	Buy → Buy	—	Truist Securities: Buy